Several other equities analysts have also recently issued reports on CLLS. Citigroup reiterated a neutral rating and set a $22.00 target price on shares of Cellectis in a research report on Friday, May 24th. Zacks Investment Research upgraded Cellectis from a hold rating to a buy rating and set a $17.00 target price on the stock in a research report on Thursday, July 18th. Finally, BidaskClub cut Cellectis from a hold rating to a sell rating in a research report on Friday, July 19th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. Cellectis has an average rating of Hold and an average price target of $31.60.
NASDAQ CLLS traded down $1.00 on Thursday, hitting $13.74. 167,839 shares of the company’s stock were exchanged, compared to its average volume of 90,678. The company has a current ratio of 9.77, a quick ratio of 9.74 and a debt-to-equity ratio of 0.07. The firm has a 50-day moving average price of $15.43. Cellectis has a fifty-two week low of $13.60 and a fifty-two week high of $29.97. The stock has a market cap of $605.36 million, a price-to-earnings ratio of -7.12 and a beta of 1.72.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Financial Gravity Wealth Inc. acquired a new stake in shares of Cellectis in the 1st quarter worth approximately $96,000. Aperio Group LLC acquired a new stake in shares of Cellectis in the 2nd quarter worth approximately $147,000. Two Sigma Investments LP acquired a new stake in shares of Cellectis in the 4th quarter worth approximately $180,000. Squarepoint Ops LLC grew its holdings in shares of Cellectis by 28.3% in the 4th quarter. Squarepoint Ops LLC now owns 16,455 shares of the biotechnology company’s stock worth $274,000 after acquiring an additional 3,626 shares during the period. Finally, Northern Trust Corp acquired a new stake in shares of Cellectis in the 4th quarter worth approximately $301,000. Institutional investors and hedge funds own 30.58% of the company’s stock.
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.
Featured Story: What is a growth and income fund?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.